Patents by Inventor Astrid Clarke
Astrid Clarke has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20180280387Abstract: The present disclosure relates to compounds that are Syk inhibitors and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, the structure of the compounds is given by Formula I: wherein R1, R2, R3, and R4 are as described herein. The present disclosure further provides pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by Syk. In certain embodiments, also disclosed are methods for treating a cancer in a subject (e.g., a human) in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt thereof, in combination with a vinca-alkaloid, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: February 28, 2018Publication date: October 4, 2018Inventors: Peter A. Blomgren, Astrid Clarke, Kevin S. Currie, Julie A. Di Paolo, Jeffrey E. Kropf, Seung H. Lee, Jennifer R. Lo, Scott A. Mitchell, Aaron C. Schmitt, Sundaramoorthi Swaminathan, Jin-Ming Xiong, Jianjun Xu, Zhongdong Zhao
-
Patent number: 10080756Abstract: Disclosed are methods for treating a cancer in a subject (e.g., a human) in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of formula I: or a pharmaceutically acceptable salt thereof, in combination with a vinca-alkaloid, or a pharmaceutically acceptable salt thereof. The subject may be very high risk or high risk for the cancer and may not respond to either agent administered as a sole therapy. The subject who has the cancer may also be refractory to at least one chemotherapy treatment, or is in relapse after treatment with chemotherapy, or both. The cancer may be a hematologic malignancy, such as leukemia or lymphoma, or a solid tumor cancer, such as pancreatic, lung and colon cancer.Type: GrantFiled: June 14, 2017Date of Patent: September 25, 2018Assignee: Gilead Sciences, Inc.Inventors: Julie Di Paolo, Astrid Clarke
-
Publication number: 20180133212Abstract: Provided herein are methods and compositions for the treatment of cancer. In particular, the methods include administration of a Bcl-2 inhibitor and a BET inhibitor.Type: ApplicationFiled: October 23, 2017Publication date: May 17, 2018Inventors: Jamie Geier Bates, Astrid Clarke, Thomas F. Kenney, Saritha Kusam, Stacey Tannheimer
-
Patent number: 9931338Abstract: The present disclosure relates to compounds that are Syk inhibitors and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, the structure of the compounds is given by Formula I: wherein R1, R2, R3, and R4 are as described herein. The present disclosure further provides pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by Syk. In certain embodiments, also disclosed are methods for treating a cancer in a subject (e.g., a human) in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt thereof, in combination with a vinca-alkaloid, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: October 20, 2016Date of Patent: April 3, 2018Assignee: Gilead Sciences, Inc.Inventors: Peter A. Blomgren, Astrid Clarke, Kevin S. Currie, Julie A. Di Paolo, Jeffrey E. Kropf, Seung H. Lee, Jennifer R. Lo, Scott A. Mitchell, Aaron C. Schmitt, Sundaramoorthi Swaminathan, Jin-Ming Xiong, Jianjun Xu, Zhongdong Zhao
-
Publication number: 20180008608Abstract: Disclosed are methods for treating a cancer in a subject (e.g., a human) in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of formula I: or a pharmaceutically acceptable salt thereof, in combination with a vinca-alkaloid, or a pharmaceutically acceptable salt thereof. The subject may be very high risk or high risk for the cancer and may not respond to either agent administered as a sole therapy. The subject who has the cancer may also be refractory to at least one chemotherapy treatment, or is in relapse after treatment with chemotherapy, or both. The cancer may be a hematologic malignancy, such as leukemia or lymphoma, or a solid tumor cancer, such as pancreatic, lung and colon cancer.Type: ApplicationFiled: June 14, 2017Publication date: January 11, 2018Inventors: Julie Di Paolo, Astrid Clarke
-
Patent number: 9707236Abstract: Disclosed are methods for treating a cancer in a subject (e.g., a human) in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of formula I: or a pharmaceutically acceptable salt thereof; in combination with a vinca-alkaloid, or a pharmaceutically acceptable salt thereof. The subject may be very high risk or high risk for the cancer and may not respond to either agent administered as a sole therapy. The subject who has the cancer may also be refractory to at least one chemotherapy treatment, or is in relapse after treatment with chemotherapy, or both. The cancer may be a hematologic malignancy, such as leukemia or lymphoma, or a solid tumor cancer, such as pancreatic, lung and colon cancer.Type: GrantFiled: July 10, 2015Date of Patent: July 18, 2017Assignee: Gilead Sciences, Inc.Inventors: Julie Di Paolo, Astrid Clarke
-
Publication number: 20170035755Abstract: The present disclosure relates to compounds that are Syk inhibitors and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, the structure of the compounds is given by Formula I: wherein R1, R2, R3, and R4 are as described herein. The present disclosure further provides pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by Syk. In certain embodiments, also disclosed are methods for treating a cancer in a subject (e.g., a human) in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt thereof, in combination with a vinca-alkaloid, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: October 20, 2016Publication date: February 9, 2017Inventors: PETER A. BLOMGREN, ASTRID CLARKE, KEVIN S. CURRIE, JULIE A. DI PAOLO, JEFFREY E. KROPF, SEUNG H. LEE, JENNIFER R. LO, SCOTT A. MITCHELL, AARON C. SCHMITT, SUNDARAMOORTHI SWAMINATHAN, JIN-MING XIONG, JIANJUN XU, ZHONGDONG ZHAO
-
Patent number: 9504684Abstract: The present disclosure relates to compounds that are Syk inhibitors and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, the structure of the compounds is given by Formula I: wherein R1, R2, R3, and R4 are as described herein. The present disclosure further provides pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by Syk. In certain embodiments, also disclosed are methods for treating a cancer in a subject (e.g., a human) in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt thereof, in combination with a vinca-alkaloid, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: July 9, 2015Date of Patent: November 29, 2016Assignee: Gilead Sciences, Inc.Inventors: Peter A. Blomgren, Astrid Clarke, Kevin S. Currie, Julie Di Paolo, Jeffrey E. Kropf, Seung H. Lee, Jennifer R. Lo, Scott A. Mitchell, Aaron C. Schmitt, Sundaramoorthi Swaminathan, Jin-Ming Xiong, Jianjun Xu, Zhongdong Zhao
-
Publication number: 20160166579Abstract: Disclosed are methods for treating a cancer in a subject (e.g., a human) in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of formula I: or a pharmaceutically acceptable salt thereof; in combination with a vinca-alkaloid, or a pharmaceutically acceptable salt thereof. The subject may be very high risk or high risk for the cancer and may not respond to either agent administered as a sole therapy. The subject who has the cancer may also be refractory to at least one chemotherapy treatment, or is in relapse after treatment with chemotherapy, or both. The cancer may be a hematologic malignancy, such as leukemia or lymphoma, or a solid tumor cancer, such as pancreatic, lung and colon cancer.Type: ApplicationFiled: July 10, 2015Publication date: June 16, 2016Inventors: Julie Di Paolo, Astrid Clarke
-
Publication number: 20160058758Abstract: The present disclosure relates to compounds that are Syk inhibitors and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, the structure of the compounds is given by Formula I: wherein R1, R2, R3, and R4 are as described herein. The present disclosure further provides pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by Syk. In certain embodiments, also disclosed are methods for treating a cancer in a subject (e.g., a human) in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt thereof, in combination with a vinca-alkaloid, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: July 9, 2015Publication date: March 3, 2016Inventors: Peter A. Blomgren, Astrid Clarke, Kevin S. Currie, Julie Di Paolo, Jeffrey E. Kropf, Seung H. Lee, Jennifer R. Lo, Scott A. Mitchell, Aaron C. Schmitt, Sundaramoorthi Swaminathan, Jin-Ming Xiong, Jianjun Xu, Zhongdong Zhao
-
Patent number: 5989897Abstract: The present invention provides the yeast genes SAS2, SAS3 and ESA1 and the proteins encoded thereby. SAS2, SAS3 and ESA1 genes of members of the genus Saccharomyces are provided, particularly the SAS2, SAS3 and ESA1 genes of S. cerevisiae. Also provided are yeast SAS2, SAS3 and ESA1 coding sequences. Specifically provided are the SAS2, SAS3 and ESA1 coding sequences of members of the genus Saccharomyces, and more specifically of S. cerevisiae. Genes of this invention comprise protein coding sequences as well as the regulatory regions that control expression of the encoded protein. Of most interest are SAS2, SAS3, and ESA1 genes of yeast including those of the genus Saccharomyces which are 90% or more homologous to the corresponding genes of S. cerevisiae. Specifically provided are DNA constructs comprising purified and isolated DNA molecules comprising SAS2, SAS3 or ESA1 coding sequences that encode proteins from a strain of S. cerevisiae.Type: GrantFiled: March 24, 1998Date of Patent: November 23, 1999Assignee: University Technology CorporationInventors: Lorraine Pillus, Astrid Clarke, Joanna Lowell, Sandra Jacobson, Cheryl Reifsnyder